SH3BP5 and Alzheimer disease: Then, given the role of NMDA receptors in Aβ-induced synaptic dysfunction, we directly tested the hypothesis that a NMDA receptor-blocking dose of memantine (5 mg/kg i.p.), clinically used to treat AD, could counteract the consolidation/retrieval failure observed in sAβ-treated rats.